The haemodynamic effects of dobutamine were studied in I4 patients with chronic congestive cardiac failure. Heart rate, central venous, pulmonary arterial, pulmonary wedge, and aortic pressures, aortic dp/dt, cardiac output, cardiac index, stroke volume, and pulmonary and systemic vascular resistances were measured or derived. Dose-response curves were obtained by recording all measurements before and after intravenous infusion of dobutamine at rates of 2.5, 5, and IO ,ug/kg per min for periods of 30 minutes each. Significant increases in mean values were observedfor cardiac output from 3.7 to 6.4 1/min (82%), for stroke volume from 44 to 64 ml (39%), and aortic dp/dt from 692 to 1414 mmHg/s (92.0 to x88.i kPa/s) (76% (Fig. i) .
of decreased vascular resistances. The drug was uniformly well tolerated. The predominant inotropic effects of dobutamine without tachycardia or arrhythmias may be valuable in severe heartfailure.
Catecholamines with predominant inotropic action have been used as an alternative to glycoside agents in conditions associated with cardiac failure. We have previously reported our experience with isoprenaline in myocardial infarction (Beregovich, and Grishman, I972) , and in the low cardiac output state following open heart surgery (Beregovich et al., I97I) . The haemodynamic and renal effects of dopamine in patients with severe and chronic congestive heart failure have also been investigated (Beregovich et al., I974; McDonald et al., I964; Rosenblum, Tai, and Lawson, I970) . These studies have demonstrated the effectiveness of such drugs as judged by clinical and haemodynamic criteria, provided their administration is based on a pharmacological understanding of their dose-response curves.
Dobutamine is a catecholamine, newly developed by systematic chemical substitutions of the side chains of isoprenaline and norepinephrine, which, in animal experiments, has proved to be almost exclusively an inotropic agent, with little direct action on the vessels. It also exhibits greatly reduced chronotropic and arrhythmogenic effects (Tuttle and Mills, in the press) ( Fig. i) .
This investigation was developed to study the dose-related effects of dobutamine in a group of Received I5 November 1974. patients with chronic congestive heart failure. Haemodynamic and renal parameters were measured during the administration of graded increments of the drug. The present report describes initial clinical observations with the use of this new inotropic agent.
Subjects and methods
Fourteen patients (8 men and 6 women) whose ages ranged from 24 tO 74 years were investigated. All had cardiac failure secondary to myocardial, coronary, or valvular disease. Patients considered for this investigation received a complete verbal and written description of the procedure and of the potential effects of the drug to be administered. Consent was subsequently obtained in writing. The patients were allocated to 2 groups according to their functional class (New York Heart Association Classification) and cardiac index at the time of the study. Group A consists of 4 patients in functional class II, clinically 'compensated', and with a cardiac index more than 3 1 minl -m-2 on basal conditions. Group B consists of io patients in functional class III or IV, with clinical evidence of severe congestive failure, and with a cardiac index less than 3 1 min -m -2. Digitalis, when previously administered, was discontinued 24 to 48 hours preceding the study. Standard haemodynamic techniques and instrumentation were used. Catheters were placed in the superior vena cava and pulmonary artery via antecubital vein cut-down or femoral 
Results
The haemodynamic effects of dobutamine are presented for Group A in Table i , and for Group B in Table 2 . Fig. 2 to 4 represent individual and average dose-response curves of pertinent parameters for patients in Group B.
In cases with minimal cardiac impairment and clinically 'compensated' (Group A), haemodynamic and renal parameters showed few changes with the dose range indicated in Table i . The inotropic activity of dobutamine, however, was manifested by moderately significant increases in cardiac output and aortic dp/dt, as well as by reduction in pulmonary wedge pressure. In contrast, patients with severe congestive heart failure (Group B) had a most significant and interesting response (Table 2) .
Cardiac index (Fig. 2) Initially at a low mean value of 2.I 1 min m 2 it increased steadily and significantly with progressive doses of the drug to a high normal value of 3.4 1 min-' m-2, representing an increase of 83 per cent above control. This augmentation in cardiac output and index was observed in each individual case.
Stroke volume (Fig. 3 ) This rose concomitantly with cardiac index to 39 per cent over control values, indicating the significant contribution of enhanced contractility upon total output, in the face of a stable preload.
Heart rate (Fig. 4 (Beregovich et al., 1972) , after cardiac surgery (Beregovich et al., I97i) , and in severe, chronic, or unresponsive heart failure (Beregovich et al., I974). Unfortunately these agents, including isoprenaline and dopamine, may induce inordinate tachycardia or arrhythmias and might be deleterious at high doses in myocardial infarction (Maroko et al., 197I) .
The pharmacological and experimental observations of Tuttle and Mills (in press) (Tuttle et al., I973) .
In this investigation, we have studied the haemodynamic and renal effects of dobutamine in a group of patients with different degrees of chronic heart failure. Progressive increments in the dose were used in order to outline dose-response curves and to assess the most effective dose range for clinical administration.
Patients without significant cardiac failure (functional class II) showed little response to dobutamine, though some parameters of cardiac perform-4-0-3.5. ance, such as cardiac output and aortic dp/dt did increase. It should be recognized, however, that aortic dp/dt, being partly dependent on peripheral vascular factors, is not a strict expression of myocardial contractility. On the other hand, patients with severe and chronic cardiac failure (functional class III and IV) showed significant improvement in their overall cardiac performance. In this particular group cardiac output increased by 82 per cent, cardiac index 83 per cent, stroke volume 39 per cent, and aortic dp/dt 76 per cent from control values. This response was achieved with only 31 per cent increase in heart rate and without tachycardia or arrhythmias. While mean aortic and pulmonary pressures remained stable, significant reductions of calculated vascular resistances and venous filling pressures were observed.
The most effective dose range in achieving the described results was 5 to io tug/kg per min. A dose of i [±g/kg per min used initially in 5 patients produced no effect and was subsequently abandoned. The dose of io ,tg/kg per min was used only in 5 patients of Group B, towards the end of this study, and once adequate tolerance had been shown to lower dosage. Doses higher than IO ,ug/kg per min, though not explored in the present investigation, might be limited by further increases in heart rate Dobutamine has proved to be a powerful inotropic agent in the context of clinical congestive heart failure, devoid of untoward side effects within the dose range used in this investigation. Longer periods of administration would be a logical next step in further evaluation of this drug. 
